156 related articles for article (PubMed ID: 32095539)
1. A prospective comparison of common toxicity criteria adverse events Version 3 and 4 in assessing oral mucositis for oral and oropharyngeal carcinoma.
Hickman M; Meade SJ; Fong C; Sanghera P; Good J; Hartley A
Tech Innov Patient Support Radiat Oncol; 2017 Mar; 1():18-21. PubMed ID: 32095539
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma.
Liu YJ; Zhu GP; Guan XY
Oral Oncol; 2012 Jun; 48(6):554-9. PubMed ID: 22289637
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Controlled Trial to Evaluate the Role and Efficacy of Oral Glutamine in the Treatment of Chemo-radiotherapy-induced Oral Mucositis and Dysphagia in Patients with Oropharynx and Larynx Carcinoma.
Pathak S; Soni TP; Sharma LM; Patni N; Gupta AK
Cureus; 2019 Jun; 11(6):e4855. PubMed ID: 31410338
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of polyacrylate silver salt/polyvinylpyrrolidone-based liquid oral gel in management of concurrence chemoradiotherapy-induced oral mucositis.
Chin HL; Chung KP; Liu HC; Chen RS; Chang HH; Chen MH
J Formos Med Assoc; 2023 Aug; 122(8):723-730. PubMed ID: 36623972
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of optimizing intensity-modulated radiation therapy plans based on measured mucosal dose adjacent to dental fillings and toxicity outcomes.
Seol SW; Aggarwal S; von Eyben R; Wang Z; Chan C; Say C; Xing L; Hara W; Yang Y; Le QT
J Appl Clin Med Phys; 2018 Sep; 19(5):444-452. PubMed ID: 29984915
[TBL] [Abstract][Full Text] [Related]
6. Radiobiological modeling of radiation-induced acute mucosal toxicity (oral mucositis and pharyngeal mucositis): A single-institutional study of head-and-neck carcinoma.
Singh B; Singh G; Oinam AS; Kumar V; Vashistha R; Sidhu MS; Singh M
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0-S1715. PubMed ID: 37147947
[TBL] [Abstract][Full Text] [Related]
7. Dynamic change of gut microbiota in head and neck concurrent chemoradiotherapy patients and its potential value in the prediction of acute oral mucositis grade as well as quality of life.
Chen Y; Ye X; Li X; Wang F; Yang J; Sun X; Yan S
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38844739
[TBL] [Abstract][Full Text] [Related]
8. Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers.
Villa A; Vollemans M; De Moraes A; Sonis S
Support Care Cancer; 2021 Oct; 29(10):6061-6068. PubMed ID: 33788003
[TBL] [Abstract][Full Text] [Related]
9. [Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial].
Chen CY; Lu TX; Zhao C; Lu LX; Han F; Sun Y
Ai Zheng; 2007 Apr; 26(4):398-402. PubMed ID: 17430660
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial.
Bentzen SM; Saunders MI; Dische S; Bond SJ
Radiother Oncol; 2001 Aug; 60(2):123-35. PubMed ID: 11439207
[TBL] [Abstract][Full Text] [Related]
11. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system.
Palazzi M; Tomatis S; Orlandi E; Guzzo M; Sangalli C; Potepan P; Fantini S; Bergamini C; Gavazzi C; Licitra L; Scaramellini G; Cantu' G; Olmi P
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):330-7. PubMed ID: 17881148
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation to establish a dose response for clinical oral mucositis in patients undergoing head-and-neck conformal radiotherapy.
Narayan S; Lehmann J; Coleman MA; Vaughan A; Yang CC; Enepekides D; Farwell G; Purdy JA; Laredo G; Nolan K; Pearson FS; Vijayakumar S
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):756-62. PubMed ID: 18417299
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer.
Bibault JE; Morelle M; Perrier L; Pommier P; Boisselier P; Coche-Dequéant B; Gallocher O; Alfonsi M; Bardet É; Rives M; Calugaru V; Chajon E; Noël G; Mecellem H; Pérol D; Dussart S; Giraud P
Cancer Radiother; 2016 Jul; 20(5):357-61. PubMed ID: 27345843
[TBL] [Abstract][Full Text] [Related]
14. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
15. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.
Anderson CM; Lee CM; Saunders DP; Curtis A; Dunlap N; Nangia C; Lee AS; Gordon SM; Kovoor P; Arevalo-Araujo R; Bar-Ad V; Peddada A; Colvett K; Miller D; Jain AK; Wheeler J; Blakaj D; Bonomi M; Agarwala SS; Garg M; Worden F; Holmlund J; Brill JM; Downs M; Sonis ST; Katz S; Buatti JM
J Clin Oncol; 2019 Dec; 37(34):3256-3265. PubMed ID: 31618127
[TBL] [Abstract][Full Text] [Related]
16. Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients.
Doi H; Fujiwara M; Suzuki H; Niwa Y; Nakayama M; Shikata T; Odawara S; Takada Y; Kimura T; Kamikonya N; Hirota S
Mol Clin Oncol; 2015 Mar; 3(2):381-386. PubMed ID: 25798271
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.
Cook A; Modh A; Ali H; Sheqwara J; Chang S; Ghanem T; Momin S; Wu V; Tam S; Money S; Han X; Fakhoury L; Movsas B; Siddiqui F
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):926-937. PubMed ID: 34808255
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with severe oral mucositis and candidiasis in patients undergoing radiotherapy for oral and oropharyngeal carcinomas: a retrospective multicenter study of 326 patients.
Nishii M; Soutome S; Kawakita A; Yutori H; Iwata E; Akashi M; Hasegawa T; Kojima Y; Funahara M; Umeda M; Komori T
Support Care Cancer; 2020 Mar; 28(3):1069-1075. PubMed ID: 31177394
[TBL] [Abstract][Full Text] [Related]
19. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
Biau J; Thivat E; Millardet C; Saroul N; Pham-Dang N; Molnar I; Pereira B; Durando X; Bourhis J; Lapeyre M
BMC Cancer; 2020 Aug; 20(1):730. PubMed ID: 32758188
[TBL] [Abstract][Full Text] [Related]
20. A phase Ⅱ prospective trial of photobiomodulation therapy in limiting oral mucositis in the treatment of locally advanced head and neck cancer patients.
Taylor JK; Mady LJ; Baddour K; Iheagwara UK; Zhai S; Ohr JP; Zandberg DP; Gorantla VC; Ferris RL; Kim S; Duvvuri U; Kubik MW; Sridharan S; Johnson JT; Holeva KD; Quinn AE; Clump DA
World J Otorhinolaryngol Head Neck Surg; 2022 Dec; 8(4):345-354. PubMed ID: 36474663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
